![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://shop.redmountainweightloss.com/cdn/shop/files/collag_large.png?v=1749226855)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs43018-025-01110-1/MediaObjects/43018_2025_1110_Fig1_HTML.png)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://www.richardlipmanmd.com/wp-content/uploads/2025/12/BENEFITSofglp1dec162025.psdTAKE2.jpg)
Quick Dispatch:
Your glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity ships.
Need Help?
Questions about glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity in your area.
The next wave of GLP-1 medications could make weight management easier — and more personalized — than ever. Drugmakers like Pfizer, Amgen, Eli Lilly, Roche, Structure Therapeutics, and Novo Nordisk are working
20.93
Roche, trailing in obesity, showcases new data for GLP-1 shot
25.19
Roche's Novel Dual GLP-1/GIP Receptor Agonist Produces Clinically Meaningful Weight Loss in Phase Ib Trial
28.66
Roche plans to become top 3 obesity player as CT-388 enters trial
20.65
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial | News
23.25
![Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://a.storyblok.com/f/176343/1920x1281/88773444bc/roche_279855.png)
Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
25.24
Carmot Therapeutics
23.57
